{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:56:40Z","timestamp":1748361400766,"version":"3.40.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,16]]},"abstract":"<jats:p>Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic malignancies and\/or hematopoietic cell transplants (HCT). Patients in our center were simultaneously screened using serological (anti-HCV) and molecular (HCV RNA) assays (February 2019\u2013November 2019).<\/jats:p>\n          <jats:p>In total, 214 patients were enrolled in this study. Three patients (1.4%) were positive for anti-HCV, and 2 (0.9%) were positive for HCV RNA. The overall percentage agreement was 99.5% (95% CI: 97.4\u201399.9). There were no cases of seronegative HCV virus infection. The positive percentage agreement was 66.7% (95% CI: 20.8\u201393.9), and the negative percentage agreement was 100.0% (95% CI: 98.2\u2013100.0). Cohen kappa coefficient was 0.80 (95% CI: 0.41\u20131.00, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001).<\/jats:p>\n          <jats:p>The diagnostic yield of screening for chronic HCV infection in patients with cancer is similar for serologic and molecular testing.<\/jats:p>","DOI":"10.1097\/md.0000000000030608","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T13:04:40Z","timestamp":1663592680000},"page":"e30608","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies"],"prefix":"10.1097","volume":"101","author":[{"given":"Harrys A.","family":"Torres","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"Department of Gastroenterology, Hepatology and Nutrition, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-9670","authenticated-orcid":false,"given":"Georgios","family":"Angelidakis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minas","family":"Economides","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalis","family":"Mustafayev","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Yibirin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3322\/caac.21403","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective.","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","article-title":"Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis.","volume":"157","author":"Torres","year":"2019","journal-title":"Gastroenterology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2005.00222.x","article-title":"Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office.","volume":"100","author":"Tien","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcv.2005.03.006","article-title":"Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients.","volume":"35","author":"Macedo de Oliveira","year":"2006","journal-title":"J Clin Virol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00126334-200210010-00005","article-title":"Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.","volume":"31","author":"George","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbmt.2015.07.033","article-title":"Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: american society for blood and marrow transplantation task force recommendations.","volume":"21","author":"Torres","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V94.4.1183.416k15_1183_1191","article-title":"Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion.","volume":"94","author":"Beld","year":"1999","journal-title":"Blood"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e3181af7a10","article-title":"Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients.","volume":"73","author":"Clifford","year":"2009","journal-title":"Neurology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00005-013-0257-7","article-title":"Seronegative hepatitis C virus infection.","volume":"62","author":"Ka\u017amierczak","year":"2014","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/JCM.37.3.484-489.1999","article-title":"Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.","volume":"37","author":"Stapleton","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1046\/j.1537-2995.2003.00445.x","article-title":"Detection of a healthy carrier of HCV with no evidence of antibodies for over four years.","volume":"43","author":"Arrojo","year":"2003","journal-title":"Transfusion"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0140-6736(18)32750-8","article-title":"How feasible is the global elimination of HCV infection?","volume":"393","author":"Wiktor","year":"2019","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cis921","article-title":"Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.","volume":"56","author":"Page","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:44:20Z","timestamp":1746333860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":14,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030608","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}